ATE520707T1
(de)
|
2001-11-13 |
2011-09-15 |
Univ Pennsylvania |
Verfahren für den nachweis und/oder die identifikation von sequenzen des adeno- assoziierten virus (aav) sowie isolation von dadurch identifizierten, neuen sequenzen
|
EP2359869B1
(en)
|
2001-12-17 |
2018-12-26 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
EP2298926A1
(en)
*
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
ES2442225T3
(es)
|
2004-04-28 |
2014-02-10 |
The Trustees Of The University Of Pennsylvania |
Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
|
DE602005026269D1
(de)
|
2004-04-28 |
2011-03-24 |
Univ Pennsylvania |
Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben
|
EP3409296A1
(en)
|
2005-04-07 |
2018-12-05 |
The Trustees of the University of Pennsylvania |
Method of increasing the function of an aav vector
|
WO2007120542A2
(en)
|
2006-03-30 |
2007-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid library and aav capsid proteins
|
DK2009990T3
(en)
*
|
2006-04-07 |
2017-01-09 |
Univ Texas |
METHODS AND COMPOSITIONS RELATED TO adenoassociated VIRUSFAGPARTIKLER
|
US9198984B2
(en)
|
2006-04-28 |
2015-12-01 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for AAV
|
US20090317417A1
(en)
*
|
2006-04-28 |
2009-12-24 |
The Trustees Of The University Of Pennsylvania |
Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
EP2425000B1
(en)
|
2009-04-30 |
2019-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
WO2010141706A1
(en)
*
|
2009-06-03 |
2010-12-09 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
SG10201908848RA
(en)
|
2010-03-29 |
2019-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
CA3066596A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
CN107828820B
(zh)
*
|
2010-10-27 |
2022-06-07 |
学校法人自治医科大学 |
用于向神经系统细胞导入基因的腺相关病毒粒子
|
WO2012109570A1
(en)
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
PL2675902T3
(pl)
|
2011-02-17 |
2019-08-30 |
The Trustees Of The University Of Pennsylvania |
Kompozycje i sposoby do zmieniania specyficzności względem tkanki i poprawy transferu genu z udziałem aav9
|
EP3699286A1
(en)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
KR20220056884A
(ko)
|
2011-04-22 |
2022-05-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
US9169299B2
(en)
*
|
2011-08-24 |
2015-10-27 |
The Board Of Trustees Of The Leleand Stanford Junior University |
AAV capsid proteins for nucleic acid transfer
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
WO2013103896A1
(en)
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
WO2013170078A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
CN105120901A
(zh)
|
2012-07-11 |
2015-12-02 |
宾夕法尼亚大学托管会 |
Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
|
PT2879719T
(pt)
|
2012-08-01 |
2018-10-08 |
Ohio State Innovation Foundation |
Administração intratecal do vírus adeno-associado 9 recombinante
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
CN111621507A
(zh)
*
|
2012-09-28 |
2020-09-04 |
北卡罗来纳-查佩尔山大学 |
靶向少突胶质细胞的aav载体
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
WO2014160092A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
EP2970884A4
(en)
|
2013-03-14 |
2016-11-02 |
Univ Florida |
PROTEINS CONTAINING DIAMINATE CARBOXYLIC ACID REPETITIONS ASSOCIATED WITH ALS
|
AU2014227766B2
(en)
*
|
2013-03-15 |
2018-10-04 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding AAV vectors
|
JP6591956B2
(ja)
|
2013-03-15 |
2019-10-16 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Mps1を治療するための組成物および方法
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
ES2897508T3
(es)
|
2013-05-31 |
2022-03-01 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
ES2739288T3
(es)
*
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
US20160369298A1
(en)
|
2013-09-26 |
2016-12-22 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
US20150098925A1
(en)
*
|
2013-10-07 |
2015-04-09 |
Kiromic, Llc |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
ES2857751T3
(es)
|
2013-10-11 |
2021-09-29 |
Massachusetts Eye & Ear Infirmary |
Métodos para predecir secuencias de virus ancestrales y usos de los mismos
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
CA2939950C
(en)
|
2014-03-09 |
2023-08-22 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
|
EA201691809A1
(ru)
|
2014-03-10 |
2017-01-30 |
ЮНИКЬЮРЕ АйПи Б.В. |
Дополнительно усовершенствованные векторы aav, продуцируемые клетками насекомого
|
SG10201810150UA
(en)
|
2014-03-17 |
2018-12-28 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression in cone cells
|
WO2015143078A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
CA2946392A1
(en)
|
2014-04-25 |
2015-10-29 |
James M. Wilson |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
WO2015175639A1
(en)
|
2014-05-13 |
2015-11-19 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
ES2856090T3
(es)
|
2014-09-24 |
2021-09-27 |
Hope City |
Variantes de vectores de virus adenoasociados para la edición genómica de alta eficacia y sus métodos
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
RU2738421C2
(ru)
|
2014-10-21 |
2020-12-14 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
EP3690024A1
(en)
*
|
2014-11-05 |
2020-08-05 |
The Research Institute at Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
RU2020109343A
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
DK3218386T3
(da)
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
Modulatorisk polynukleotid
|
RU2727015C2
(ru)
*
|
2014-11-21 |
2020-07-17 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Векторы aav, нацеленные на центральную нервную систему
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
EP3233131A1
(en)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Gene therapy for juvenile batten disease
|
ES2900973T3
(es)
|
2015-01-07 |
2022-03-21 |
UNIV AUTòNOMA DE BARCELONA |
Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
|
NZ734019A
(en)
|
2015-01-16 |
2023-01-27 |
Univ Washington |
Novel micro-dystrophins and related methods of use
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
WO2016141078A1
(en)
|
2015-03-02 |
2016-09-09 |
Avalanche Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
CA2978917A1
(en)
|
2015-03-10 |
2016-09-15 |
The Trustees Of Columbia University In The City Of New York |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
WO2016154344A1
(en)
*
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
JP6851319B2
(ja)
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系
|
EP3291765A4
(en)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
METHODS OF DELIVERING AN AGENT TO THE EYE
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
JP6805174B2
(ja)
*
|
2015-05-12 |
2020-12-23 |
アメリカ合衆国 |
神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むaav分離株及び融合タンパク質
|
MA48852A
(fr)
|
2015-05-13 |
2020-04-01 |
Univ Pennsylvania |
Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
US10509045B2
(en)
|
2015-05-29 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Methods for diagnosing Huntington's disease
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
|
EP3872085B1
(en)
*
|
2015-07-30 |
2023-03-01 |
Massachusetts Eye & Ear Infirmary |
Ancestral aav sequences and uses thereof
|
CN108472314A
(zh)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
修饰的细胞和治疗方法
|
AU2016302335B2
(en)
|
2015-08-06 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
GLP-1 and use thereof in compositions for treating metabolic diseases
|
CA2996001A1
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
WO2017040524A1
(en)
|
2015-08-31 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Aav-epo for treating companion animals
|
JP7261583B2
(ja)
|
2015-09-24 |
2023-04-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
補体媒介性疾患を処置するための組成物及び方法
|
CA2996420A1
(en)
|
2015-09-28 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
WO2017066764A2
(en)
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
WO2017070516A1
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
US20200181644A1
(en)
*
|
2015-10-22 |
2020-06-11 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial aav3 capsid library
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
WO2017075119A1
(en)
|
2015-10-28 |
2017-05-04 |
The Trustees Of The Univeresity Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
RU2743792C2
(ru)
|
2015-11-05 |
2021-02-26 |
Бамбу Терапьютикс, Инк. |
Модифицированные гены атаксии фридрейха и векторы для генной терапии
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
AU2016366549B2
(en)
*
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
EP4215605A1
(en)
|
2015-12-11 |
2023-07-26 |
The Trustees of The University of Pennsylvania |
Scalable purification method for aav8
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
SG10201913266UA
(en)
|
2015-12-11 |
2020-02-27 |
Massachusetts Eye & Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
CN115957350A
(zh)
|
2015-12-11 |
2023-04-14 |
宾夕法尼亚州大学信托人 |
用于治疗家族性高胆固醇血症的基因疗法
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
WO2017100704A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
RU2762747C2
(ru)
|
2015-12-14 |
2021-12-22 |
Зе Трастис Оф Зе Юниверсити Оф Пенсильвания |
Генная терапия офтальмологических нарушений
|
WO2017106345A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
JP7082050B2
(ja)
*
|
2015-12-14 |
2022-06-07 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脊髄性筋萎縮症の処置において有用なアデノ-関連ウイルスベクター
|
US11826433B2
(en)
*
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
AU2017215211C1
(en)
|
2016-02-03 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
LT3411484T
(lt)
|
2016-02-05 |
2023-11-27 |
Emory University |
Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
|
EP4094780A3
(en)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
AU2017246643B2
(en)
|
2016-04-04 |
2022-08-04 |
University Of Florida Research Foundation, Incorporated |
Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF EXPRESSION OF GRAINHEAD PROTEIN
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
KR20230125339A
(ko)
|
2016-04-15 |
2023-08-29 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
WO2017180936A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
SG11201808457PA
(en)
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
CA3019423A1
(en)
*
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
WO2017180857A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating hemophilia a
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3452495B1
(en)
*
|
2016-05-03 |
2021-06-23 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
WO2017197355A2
(en)
|
2016-05-13 |
2017-11-16 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
CN109831916B
(zh)
|
2016-05-18 |
2023-07-21 |
沃雅戈治疗公司 |
治疗亨廷顿氏舞蹈病的组合物和方法
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
US11504435B2
(en)
|
2016-06-13 |
2022-11-22 |
The University Of North Carolina At Chapel Hill |
Optimized CLN1 genes and expression cassettes and their use
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
EP3481958A4
(en)
|
2016-07-08 |
2019-12-25 |
The Trustees of The University of Pennsylvania |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF RDH12-RELATED DISORDERS AND DISEASES
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
EP3491008A2
(en)
*
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
CN116286986A
(zh)
|
2016-07-29 |
2023-06-23 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体和其使用方法
|
EP3831281A1
(en)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
KR20190075964A
(ko)
*
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
AU2017346885B2
(en)
|
2016-10-18 |
2021-10-21 |
Intima Bioscience, Inc. |
Tumor infiltrating lymphocytes and methods of therapy
|
WO2018075798A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
CA3048044A1
(en)
|
2016-12-30 |
2018-07-05 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating wilson's disease
|
KR20190100318A
(ko)
|
2016-12-30 |
2019-08-28 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
페닐케톤뇨증을 치료하기 위한 유전자 치료
|
WO2018134168A1
(en)
|
2017-01-17 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
EP3576760A2
(en)
|
2017-02-01 |
2019-12-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
US11920156B2
(en)
|
2017-02-09 |
2024-03-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (NK) cells and compositions and methods thereof
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
JP7237843B2
(ja)
|
2017-02-21 |
2023-03-13 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
修飾されたaavキャプシドタンパク質およびその使用
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
SG11201907714UA
(en)
*
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
SG10201913833PA
(en)
*
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
AU2018228881B2
(en)
|
2017-03-01 |
2024-01-25 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
US11376321B2
(en)
|
2017-03-02 |
2022-07-05 |
Genethon |
Method for removing anti-AAV antibodies from a blood-derived composition
|
AU2018235838B2
(en)
|
2017-03-16 |
2023-12-14 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
KR20240039221A
(ko)
|
2017-03-16 |
2024-03-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
EP3601558A4
(en)
|
2017-03-24 |
2021-01-06 |
Lankenau Institute for Medical Research |
METHODS AND COMPOSITIONS FOR CAPTURE OF INDUCTIBLE EXTRACELLULAR MEMBRANE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS
|
SG11201909136PA
(en)
|
2017-03-31 |
2019-10-30 |
Staidson Beijing Biopharmaceuticals Co Ltd |
Shrna expression cassette, polynucleotide sequence carrying the same, and use thereof
|
US11499154B2
(en)
|
2017-04-10 |
2022-11-15 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
IL307936A
(en)
|
2017-04-14 |
2023-12-01 |
Regenxbio Inc |
Treatment for mucopolysaccharidosis 2 with the help of recombinant human iduronate-2 suplatase (ids) produced by human neuron or glial cells
|
AU2018255293B2
(en)
*
|
2017-04-17 |
2024-03-07 |
University Of Florida Research Foundation, Incorporated |
Regulation of RAN translation by PKR and eIF2a-P pathways
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
US11752181B2
(en)
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
CN110913866A
(zh)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
WO2018208972A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質(aap)依存性を改変する方法および組成物
|
JP7273730B2
(ja)
|
2017-05-11 |
2023-05-15 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
神経セロイドリポフスチン症のための遺伝子療法
|
CA3098592A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
JP2020527335A
(ja)
|
2017-06-14 |
2020-09-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
WO2019006418A2
(en)
*
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
SG11201912631PA
(en)
|
2017-07-06 |
2020-01-30 |
Univ Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
WO2019008157A1
(en)
|
2017-07-07 |
2019-01-10 |
Genethon |
NOVEL POLYNUCLEOTIDES ENCODING HUMAN FKRP PROTEIN
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
CN110945018A
(zh)
|
2017-07-27 |
2020-03-31 |
诺华股份有限公司 |
抗脱落酶的trem2变体
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
CN110709511A
(zh)
|
2017-08-28 |
2020-01-17 |
加利福尼亚大学董事会 |
腺相关病毒衣壳变体及其使用方法
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Sod1二重発現ベクターおよびその使用
|
BR112020005249A2
(pt)
|
2017-09-22 |
2020-09-24 |
The Trustees Of The University Of Pennsylvania |
terapia de gene para tratar mucopolissacaridose tipo ii
|
JP7350337B2
(ja)
|
2017-09-26 |
2023-09-26 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. |
神経障害の処置においてranタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症(als)の治療
|
US20200283500A1
(en)
|
2017-10-18 |
2020-09-10 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
CA3079568A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
WO2019077159A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
|
CA3083472A1
(en)
|
2017-11-27 |
2019-05-31 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
EP3717653A4
(en)
|
2017-11-30 |
2021-12-01 |
The Trustees of The University of Pennsylvania |
GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIA
|
WO2019108856A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iiib
|
WO2019126329A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos Llc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
JP2021511020A
(ja)
|
2018-01-17 |
2021-05-06 |
アドリーナス セラピューティクス, インコーポレイテッド |
21−ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
F8遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
WO2019168961A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
WO2019169004A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
JP7304878B2
(ja)
*
|
2018-03-16 |
2023-07-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
キャプシド改変による組織特異的遺伝子送達の増加
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
JP7374119B2
(ja)
|
2018-04-05 |
2023-11-06 |
ジェネトン |
減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
|
WO2019212921A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Scalable clarification process for recombinant aav production
|
EP3788165A1
(en)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
US20210207168A1
(en)
|
2018-05-08 |
2021-07-08 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
EP3790627A2
(en)
|
2018-05-09 |
2021-03-17 |
BioMarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
CA3100006A1
(en)
|
2018-05-11 |
2019-11-14 |
Massachusetts Eye And Ear Infirmary |
Altering tissue tropism of adeno-associated viruses
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
EP3793616A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
KR102662837B1
(ko)
|
2018-06-04 |
2024-05-03 |
카리디 바이오테라퓨틱스, 인크. |
바이러스 치료법의 강화를 위한 세포-기반 비히클
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
EP3807404A1
(en)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
EP3807405A2
(en)
|
2018-06-14 |
2021-04-21 |
REGENXBIO Inc. |
Anion exchange chromatography for recombinant aav production
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
EP3830107A2
(en)
|
2018-08-03 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
CN112567027A
(zh)
|
2018-08-10 |
2021-03-26 |
再生生物股份有限公司 |
用于重组aav生产的可扩展方法
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CA3111076A1
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
AU2019346447A1
(en)
|
2018-09-26 |
2021-04-29 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
WO2020069461A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
CA3114869C
(en)
|
2018-10-01 |
2023-10-03 |
Toru Miyazaki |
Therapeutic agent for neurodegenerative disease
|
SG11202102942VA
(en)
|
2018-10-01 |
2021-04-29 |
Univ Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
CA3115248A1
(en)
*
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
US20210324483A1
(en)
|
2018-10-15 |
2021-10-21 |
Regenxbio Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
KR20210082205A
(ko)
|
2018-10-22 |
2021-07-02 |
유니버시티 오브 로체스터 |
레트로바이러스 인테그라제-Cas9 융합 단백질을 이용한 유도된 비상동 DNA 삽입에 의한 게놈 편집
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP3876951A1
(en)
|
2018-11-06 |
2021-09-15 |
Calidi Biotherapeutics, Inc. |
Enhanced systems for cell-mediated oncolytic viral therapy
|
KR20210093954A
(ko)
|
2018-11-16 |
2021-07-28 |
아스텔라스세이야쿠 가부시키가이샤 |
유트로핀 유전자를 표적으로 하여 근이영양증을 치료하는 방법
|
US20220008466A1
(en)
|
2018-11-21 |
2022-01-13 |
Indapta Therapeutics, Inc |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
KR20210135987A
(ko)
|
2018-11-30 |
2021-11-16 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd86 변이체 면역조절 단백질 및 그의 용도
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
JP2022516283A
(ja)
|
2019-01-04 |
2022-02-25 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
ウイルソン病を処置するための遺伝子治療構築物
|
CN113544267A
(zh)
|
2019-01-14 |
2021-10-22 |
罗切斯特大学 |
使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
|
AU2020208467A1
(en)
|
2019-01-18 |
2021-08-05 |
Voyager Therapeutics, Inc. |
Methods and systems for producing AAV particles
|
CN113924115A
(zh)
|
2019-01-31 |
2022-01-11 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
CN113710281A
(zh)
|
2019-02-22 |
2021-11-26 |
宾夕法尼亚州大学信托人 |
用于治疗grn相关成人发作性神经退行性病变的重组腺相关病毒
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
CR20210444A
(es)
|
2019-02-25 |
2021-11-02 |
Novartis Ag |
Composiciones y métodos para tratar distrofia cristalina de bietti
|
CA3130055A1
(en)
|
2019-02-26 |
2020-09-03 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
CA3176660A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
TW202102525A
(zh)
|
2019-03-21 |
2021-01-16 |
美商史崔德生物公司 |
重組腺相關病毒載體
|
US20220204574A1
(en)
|
2019-03-25 |
2022-06-30 |
Genethon |
Production of large-sized quasidystrophins using overlapping aav vectors
|
EP3946467A1
(en)
|
2019-04-03 |
2022-02-09 |
REGENXBIO Inc. |
Gene therapy for eye pathologies
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
FI3953483T3
(fi)
|
2019-04-11 |
2023-11-30 |
Regenxbio Inc |
Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
|
TW202332458A
(zh)
|
2019-04-19 |
2023-08-16 |
美商銳進科斯生物股份有限公司 |
腺相關病毒載體調配物及方法
|
EP3959323A1
(en)
|
2019-04-24 |
2022-03-02 |
REGENXBIO Inc. |
Fully-human post-translationally modified antibody therapeutics
|
MX2021013266A
(es)
*
|
2019-04-29 |
2021-11-17 |
Univ Pennsylvania |
Nuevas capsides de aav y composiciones que las contienen.
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
AR118928A1
(es)
|
2019-05-14 |
2021-11-10 |
Biomarin Pharm Inc |
Métodos de redosificación de vectores de terapia génica
|
MX2021014478A
(es)
|
2019-05-28 |
2022-01-06 |
Astellas Pharma Inc |
Metodo para tratar distrofia muscular por direccionamiento del gen dmpk.
|
JP2022534119A
(ja)
|
2019-05-30 |
2022-07-27 |
ソリッド・バイオサイエンシーズ・インコーポレーテッド |
組換えヘルペスウイルスベクター
|
WO2020261178A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
CA3145662A1
(en)
|
2019-07-02 |
2021-01-07 |
M6P Therapeutics |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
CA3146718A1
(en)
|
2019-07-11 |
2021-01-14 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated virus
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
JP2022544015A
(ja)
|
2019-07-23 |
2022-10-17 |
ユニバーシティ オブ ロチェスター |
CRISPR-Casでの標的化されたRNA切断
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
WO2021033635A1
(en)
|
2019-08-16 |
2021-02-25 |
Modalis Therapeutics Corporation |
Method for treating muscular dystrophy by targeting lama1 gene
|
US20220288235A1
(en)
*
|
2019-08-20 |
2022-09-15 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
MX2022002366A
(es)
|
2019-08-26 |
2022-07-19 |
Regenxbio Inc |
Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
CN114555814A
(zh)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白-连接子聚合蛋白
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US20230270885A2
(en)
|
2019-09-19 |
2023-08-31 |
Genethon |
Gene therapy expression system alleviating cardiac toxicity of fkrp
|
EP4038194A1
(en)
|
2019-10-04 |
2022-08-10 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
JP2022552262A
(ja)
|
2019-10-07 |
2022-12-15 |
リジェネックスバイオ インコーポレイテッド |
アデノ随伴ウイルスベクター医薬組成物および方法
|
AU2020361533A1
(en)
|
2019-10-08 |
2022-04-28 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
JP2022552260A
(ja)
|
2019-10-08 |
2022-12-15 |
エクスハウラ リミテッド |
眼治療のための組成物および方法
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療c型尼曼—匹克病之腺相關病毒載體
|
US20220396808A1
(en)
*
|
2019-11-08 |
2022-12-15 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
US20230002451A1
(en)
*
|
2019-11-08 |
2023-01-05 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
BR112022009895A2
(pt)
|
2019-11-28 |
2022-08-09 |
Regenxbio Inc |
Construtos de terapia de gene de microdistrofina e usos dos mesmos
|
EP4073257A1
(en)
|
2019-12-09 |
2022-10-19 |
UCL Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
KR20220112283A
(ko)
|
2019-12-10 |
2022-08-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
Hunter 질환 치료용 아데노-연합된 바이러스 벡터
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
CA3167685A1
(en)
|
2020-01-22 |
2021-07-29 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
KR20220133900A
(ko)
|
2020-01-29 |
2022-10-05 |
리젠엑스바이오 인크. |
점액다당류증 iva의 치료
|
US20230088992A1
(en)
|
2020-01-29 |
2023-03-23 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
TW202140781A
(zh)
|
2020-02-02 |
2021-11-01 |
賓州大學委員會 |
有用於治療gm1神經節苷脂症之組成物
|
CA3168903A1
(en)
|
2020-02-07 |
2021-08-12 |
University Of Rochester |
Ribozyme-mediated rna assembly and expression
|
US20230078498A1
(en)
|
2020-02-07 |
2023-03-16 |
University Of Rochester |
Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
|
AU2021218703A1
(en)
|
2020-02-14 |
2022-07-28 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating CDKL5 deficiency disorder
|
EP4110373A1
(en)
|
2020-02-28 |
2023-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
KR20220149590A
(ko)
|
2020-03-02 |
2022-11-08 |
테나야 테라퓨틱스, 인코포레이티드 |
심근세포-발현 마이크로rna에 의한 유전자 벡터 제어
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
US11191784B2
(en)
|
2020-03-11 |
2021-12-07 |
The Trustees Of The University Of Pennsylvania |
Methods and composition for gene delivery using an engineered viral particle
|
EP4121544A1
(en)
|
2020-03-19 |
2023-01-25 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
EP4127169A1
(en)
|
2020-03-27 |
2023-02-08 |
University of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
US20230103771A1
(en)
|
2020-03-27 |
2023-04-06 |
University Of Rochester |
CRISPR-Cas13 crRNA Arrays
|
AU2021245031A1
(en)
|
2020-03-27 |
2022-11-03 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
EP4126910A1
(en)
|
2020-04-01 |
2023-02-08 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
BR112022020444A2
(pt)
|
2020-04-10 |
2022-11-29 |
Sola Biosciences Llc |
Composições e métodos para o tratamento de distúrbios de agregação de proteínas
|
EP4135841A1
(en)
|
2020-04-15 |
2023-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
JP2023523429A
(ja)
|
2020-04-22 |
2023-06-05 |
インダプタ セラピューティクス インコーポレイテッド |
ナチュラルキラー(nk)細胞組成物およびそれを生成させるための方法
|
JP2023524414A
(ja)
|
2020-04-28 |
2023-06-12 |
ソラ・バイオサイエンシズ・エルエルシー |
Tdp-43プロテイノパチーの処置のための組成物および方法
|
JP2023524291A
(ja)
*
|
2020-05-05 |
2023-06-09 |
デューク ユニバーシティ |
異種間適合性アデノ随伴ウイルス組成物およびその使用方法
|
US20230304034A1
(en)
|
2020-05-12 |
2023-09-28 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
TW202208622A
(zh)
|
2020-05-12 |
2022-03-01 |
賓州大學委員會 |
用於治療克拉培氏病之組成物
|
WO2021230987A1
(en)
|
2020-05-13 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
CA3183171A1
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating slc26a4-associated hearing loss
|
AR122079A1
(es)
|
2020-05-13 |
2022-08-10 |
Akouos Inc |
Composiciones y métodos para tratar la perdida auditiva asociada a kcnq4
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
CN116096737A
(zh)
|
2020-06-05 |
2023-05-09 |
索拉生物科学有限公司 |
用于治疗突触核蛋白病的组合物和方法
|
AU2021292200A1
(en)
|
2020-06-17 |
2023-02-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
WO2021255245A2
(en)
|
2020-06-19 |
2021-12-23 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
CN115885043A
(zh)
*
|
2020-07-07 |
2023-03-31 |
德克萨斯大学系统董事会 |
用于dwarf开放阅读框的腺相关病毒载体
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
CN116194587A
(zh)
|
2020-07-10 |
2023-05-30 |
吉尼松公司 |
一种新的肌肉特异性启动子
|
KR20230038503A
(ko)
|
2020-07-13 |
2023-03-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
샤르코-마리-투스 질환의 치료에 유용한 조성물
|
WO2022015916A1
(en)
|
2020-07-15 |
2022-01-20 |
University Of Rochester |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
CN115960921A
(zh)
*
|
2020-07-29 |
2023-04-14 |
舒泰神(北京)生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
BR112023003023A2
(pt)
|
2020-08-17 |
2023-04-11 |
Massachusetts Inst Technology |
Abordagens de terapia com gene shank3
|
EP4200429A1
(en)
|
2020-08-24 |
2023-06-28 |
The Trustees of The University of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
KR20230058102A
(ko)
|
2020-08-26 |
2023-05-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Grn 관련 성인 발병 신경변성 치료를 위한 재조합 아데노-연관 바이러스
|
CA3194019A1
(en)
|
2020-09-04 |
2022-03-10 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
WO2022076711A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
WO2022076549A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
AU2021356645A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
CA3197342A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
KR20230118075A
(ko)
|
2020-10-09 |
2023-08-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
파브리병 치료를 위한 조성물 및 방법
|
AR123838A1
(es)
|
2020-10-18 |
2023-01-18 |
Univ Pennsylvania |
Vector mejorado de virus adenoasociado (aav) y usos de este
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
CA3195967A1
(en)
|
2020-10-28 |
2022-05-05 |
Xu Wang |
Vectorized anti-tnf-? antibodies for ocular indications
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
CA3196964A1
(en)
|
2020-10-29 |
2022-05-05 |
Xu Wang |
Vectorized tnf-alpha antagonists for ocular indications
|
EP4236974A2
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized factor xii antibodies and administration thereof
|
CA3196778A1
(en)
|
2020-11-02 |
2022-05-05 |
Biomarin Pharmaceutical, Inc. |
Process for enriching adeno-associated virus
|
MX2023005218A
(es)
|
2020-11-03 |
2023-05-16 |
Pfizer |
Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico.
|
US20240024507A1
(en)
|
2020-12-01 |
2024-01-25 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
TW202237644A
(zh)
|
2020-12-01 |
2022-10-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
JP2023551911A
(ja)
|
2020-12-01 |
2023-12-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アンジェルマン症候群の治療のための組成物及びその使用
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
AU2021403076A1
(en)
|
2020-12-16 |
2023-06-29 |
Regenxbio Inc. |
Method of producing a recombinant adeno-associated virus particle
|
AU2021404944A1
(en)
|
2020-12-23 |
2023-07-06 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
IL304006A
(en)
|
2020-12-29 |
2023-08-01 |
Akouos Inc |
Compositions and methods for treating hearing loss and/or vision loss associated with CLRN1
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
CA3205209A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
MX2023008738A
(es)
*
|
2021-01-25 |
2023-09-12 |
Trames Bio Inc |
Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático.
|
BR112023015303A2
(pt)
|
2021-02-01 |
2023-11-14 |
Regenxbio Inc |
Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito
|
WO2022169774A1
(en)
*
|
2021-02-02 |
2022-08-11 |
University Of Massachusetts |
Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
|
WO2022170146A1
(en)
|
2021-02-05 |
2022-08-11 |
Maze Therapeutics, Inc. |
Vectors comprising stuffer polynucleotide sequences
|
AU2022218706A1
(en)
*
|
2021-02-09 |
2023-09-28 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
KR20230145386A
(ko)
|
2021-02-10 |
2023-10-17 |
리젠엑스바이오 인크. |
재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료
|
EP4298227A1
(en)
|
2021-02-26 |
2024-01-03 |
Takeda Pharmaceutical Company Limited |
Composition and methods for the treatment of fabry disease
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
KR20230159837A
(ko)
|
2021-03-19 |
2023-11-22 |
아드레나스 테라퓨틱스, 인코포레이티드 |
21-하이드록실라제 결핍에 대한 유전자 요법
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
WO2022216749A1
(en)
|
2021-04-05 |
2022-10-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
AU2022258312A1
(en)
|
2021-04-12 |
2023-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
EP4326753A2
(en)
|
2021-04-23 |
2024-02-28 |
University of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
MX2023012513A
(es)
|
2021-04-23 |
2023-12-15 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen.
|
JP2024517143A
(ja)
|
2021-04-26 |
2024-04-19 |
リジェネックスバイオ インコーポレイテッド |
ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与
|
CN117377500A
(zh)
|
2021-04-26 |
2024-01-09 |
阿雷克森国际制药有限公司 |
具有改善的组织向性的腺相关病毒载体衣壳
|
EP4334454A2
(en)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Novel aav vectors and methods and uses thereof
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
JP2024520815A
(ja)
*
|
2021-06-08 |
2024-05-24 |
エヌエフ2 セラピューティクス, インコーポレイテッド |
神経線維腫性障害を処置するための組成物および方法
|
WO2022266452A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
WO2022272056A2
(en)
*
|
2021-06-24 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
CA3225985A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
IL309742A
(en)
|
2021-07-08 |
2024-02-01 |
Tenaya Therapeutics Inc |
Optimal expression cassettes for gene therapy
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
CN118076744A
(zh)
*
|
2021-07-23 |
2024-05-24 |
杜克大学 |
腺相关病毒组合物及其使用方法
|
CN117794561A
(zh)
|
2021-07-30 |
2024-03-29 |
宫崎彻 |
缺血性疾病的治疗剂
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
CA3229998A1
(en)
*
|
2021-08-25 |
2023-03-02 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease
|
AU2022335593A1
(en)
*
|
2021-08-25 |
2024-03-14 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
JP7175044B1
(ja)
|
2021-09-24 |
2022-11-18 |
株式会社中山事務所 |
波力発電装置
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating KCNQ4-related hearing loss
|
WO2023056399A1
(en)
|
2021-10-02 |
2023-04-06 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
TW202333776A
(zh)
|
2021-10-12 |
2023-09-01 |
美商阿斯帕醫療公司 |
用於治療腦白質失養症的方法及組合物
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
TW202334436A
(zh)
|
2021-11-02 |
2023-09-01 |
美商航海家醫療公司 |
Aav衣殼變異體及其用途
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023091948A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
WO2023114901A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023135316A1
(en)
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
Gene therapy composition and treatment for dystrophin-related cardiomyopathy
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
TW202346599A
(zh)
|
2022-02-08 |
2023-12-01 |
美商航海家醫療公司 |
Aav衣殼變異體及其用途
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023230409A1
(en)
*
|
2022-05-24 |
2023-11-30 |
Kate Therapeutics, Inc. |
Compositions for treating xlmtm
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024064856A1
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
WO2024130067A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|